ISAL 2025 | Novel approaches in APL: combining oral arsenic with ATRA
Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, comments on novel approaches being explored for the treatment of acute promyelocytic leukemia (APL). She highlights the potential of oral arsenic in combination with all-trans retinoic acid (ATRA), especially in the consolidation phase, and notes that the oral formulation could be particularly useful in reducing the number of visits to outpatient clinics. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, the next frontier is the use of oral arsenic in combination with ATRA. And this combination has been used in Chinese trials and also in Australasian trials, also from the University of Hong Kong and has shown very high efficacy in these patients. And we have not used it in Europe or the US and we’re looking forward to being able to use this. This is a very attractive drug, especially in the consolidation phase, because we are now used to using ATO, intravenous ATO plus ATRA during consolidation in the outpatient setting...
Yes, the next frontier is the use of oral arsenic in combination with ATRA. And this combination has been used in Chinese trials and also in Australasian trials, also from the University of Hong Kong and has shown very high efficacy in these patients. And we have not used it in Europe or the US and we’re looking forward to being able to use this. This is a very attractive drug, especially in the consolidation phase, because we are now used to using ATO, intravenous ATO plus ATRA during consolidation in the outpatient setting. And of course, having an oral formulation of the drug could be very, very useful in this setting outpatient. And so to reduce also the number of visits that the patient has to do in the outpatient clinic. We now use IV-ATO five days a week in the outpatient clinic, and we could reduce maybe the visits of the patients to twice a week. Compliance is a big issue. Of course, we have to make sure that patients take the drug. So there are issues there, but I think that that is the most promising drug we have.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
